A Phase 3 interventional study of Topical roflumilast in Chronic Plaque Psoriasis, sponsored by Arcutis Biotherapeutics, Inc.. Completed at 85 sites in 3 countries. Open to participants aged 2 Years to 11 Years. Per ClinicalTrials.gov, last updated 2026-09-09.
Sponsored by Arcutis Biotherapeutics, Inc. · Phase 3, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 17 studies testing roflumilast in Psoriasis — 3 open to participants now, 3 under way, none of them phase 3. Roflumilast · Psoriasis.
Among the 17 studies testing roflumilast in Psoriasis, this one is the 4th largest by enrollment, is one of 3 that started in 2020, is one of 5 in phase 3, and was the 8th registered.
2,030 studies on the registry are indexed under Psoriasis; 276 are open to participants now.
Browse Psoriasis studies →3 of the 17 studies testing roflumilast in Psoriasis are open now, in 2 countries. Recruiting first, the newest first:
Modern Research Associates, PLLC · Sites in United States
Ahmed Ibrahim · Sites in Egypt
Ages 18+
University of California, San Francisco · Sites in United States
Ages 18+
By country, each count listing its studies:
Roflumilast: first FDA approval 2011 (DALIRESP), first EMA approval 2010. What it is approved for, and how studies give it, is on its page →
Of the 173 Psoriasis studies recruiting now, 91 (53%) set no upper age limit and 66 (38%) stop at 75 or younger; 25 take children under 18; 40 take healthy volunteers.
This study: 2 Years to 11 Years · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
17 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 2 · Phase 2 9 · Phase 3 6 · Phase 4 2
First in 2008; this study’s year is marked. 3 started in 2020.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 337 is above the median of 75 across 1,567 interventional studies indexed under Psoriasis.
Median enrollment 46 across the 17 interventional studies. Of the 13 that completed or were terminated, 9 (69%) have results posted.
This tab as a report to print or save as PDF → With an account.
12 of 17 have an industry lead sponsor. The 9 most frequent:
Arcutis Biotherapeutics, Inc. is the lead sponsor of 26 studies on the registry; 2 are open to participants now.
Of its 24 completed or terminated interventional studies of FDA-regulated products, 20 (83%) have results posted.
12 studies in Psoriasis by Arcutis Biotherapeutics, Inc.: none open now, none under way, none of them phase 3. Of 12 finished, 10 (83%) have results posted.
Among the 12 studies in Psoriasis by Arcutis Biotherapeutics, Inc., this one is the 4th largest by enrollment, is one of 4 that started in 2020, is one of 4 in phase 3, and was the 8th registered.
Arcutis Biotherapeutics, Inc.’s Psoriasis studies by the year they started, since 2017.
1 of the studies testing roflumilast in Psoriasis that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT07725822Modern Research Associates, PLLCAn Open Label Trial to Evaluate Efficacy and Safety of Roflumilast 0.3% Cream for Chronic Plaque and Nail Psoriasis | 2027-07 |
Add it to your calendar (.ics) → With an account.
Among the 17 studies testing roflumilast in Psoriasis, from their registry updates:
Among Arcutis Biotherapeutics, Inc.’s 12 in Psoriasis:
Nothing recorded among them since 2026-09-25.
This tab as a report to print or save as PDF → With an account.
This study will assess the safety and efficacy of ARQ-151 cream applied once a day for 24 weeks by subjects with chronic plaque psoriasis
This is an open-label study in which ARQ-151 cream is applied once daily x 24 weeks to subjects with psoriasis
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Subjects with chronic plaque psoriasis who meet eligibility criteria and:
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Childbearing potential
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraception
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Investigational drug or device
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Drug: Topical roflumilast
Active treatment
Also known as: ARQ-151 Cream 0.3%
Percentage of Participants With ≥1 Treatment-Emergent Adverse Events (TEAEs)
The percentage of participants with ≥TEAE is reported.
Time frame: Up to 24 weeks
Percentage of Participants With ≥1 Serious Adverse Events (SAEs)
The percentage of participants with ≥1 SAE is reported.
Time frame: Up to 24 weeks
Achievement of an Investigator Global Assessment (IGA) Score of 'Clear' or 'Almost Clear' Over Time
The percentage of participants achieving an IGA score of 0 or 1 is reported. The IGA is a 5-point scale assessing the severity of skin issues, with scores ranging from 0 ('clear') to 4 ('severe'), and higher scores indicate greater symptom severity.
Time frame: Weeks 4, 12, and 24
Duration of Response (DOR) for Participants Achieving an IGA Score of 'Clear' or 'Almost Clear'
The Kaplan-Meier (KM) median DOR (days) of IGA score of clear or almost clear is reported. The IGA is a 5-point scale assessing the severity of skin issues, with scores ranging from 0 ('clear') to 4 ('severe'), and higher scores indicate greater symptom severity. The duration of response starts with the first assessment of clear or almost clear, which could be as early as the Week 2 assessment in the feeder study, and continues until the participant's disease worsens or completes their involvement in the study. Therefore, the time variable could be as long as 30 weeks, 6 weeks in the feeder study plus 24 weeks in the ARQ-151-306 study.
Time frame: Up to Week 30
Return to IGA Score of ≥2 After Achieving an IGA Score of 'Clear' or 'Almost Clear'
The percentage of participants worsening to IGA Score of ≥2 after achieving an IGA score of clear or almost clear is reported. The IGA is a 5-point scale assessing the severity of skin issues, with scores ranging from 0 ('clear') to 4 ('severe'), and higher scores indicate greater symptom severity.
Time frame: Up to Week 24
Achievement of a 50% Reduction in Psoriasis Area Severity Index (PASI-50) Score Over Time
The percentage of participants achieving PASI-50 is reported. The PASI is widely used for the measurement of severity of psoriasis. PASI combines the assessment of the severity of lesions and the area affected into a single score in the range from 0 (no disease) to 72 (maximal disease), with higher scores indicating greater symptom severity.
Time frame: Weeks 4, 12, and 24
Achievement of a 75% Reduction in Psoriasis Area Severity Index (PASI-75) Score Over Time
The percentage of participants achieving PASI-75 is reported. The PASI is widely used for the measurement of severity of psoriasis. PASI combines the assessment of the severity of lesions and the area affected into a single score in the range from 0 (no disease) to 72 (maximal disease), with higher scores indicating greater symptom severity.
Time frame: Weeks 4, 12, and 24
Achievement of a 90% Reduction in Psoriasis Area Severity Index (PASI-90) Score Over Time
The percentage of participants achieving PASI-90 is reported. The PASI is widely used for the measurement of severity of psoriasis. PASI combines the assessment of the severity of lesions and the area affected into a single score in the range from 0 (no disease) to 72 (maximal disease), with higher scores indicating greater symptom severity.
Time frame: Weeks 4, 12, and 24
Achievement of a 100% Reduction in Psoriasis Area Severity Index (PASI-100) Score Over Time
The percentage of participants achieving PASI-100 is reported. The PASI is widely used for the measurement of severity of psoriasis. PASI combines the assessment of the severity of lesions and the area affected into a single score in the range from 0 (no disease) to 72 (maximal disease), with higher scores indicating greater symptom severity.
Time frame: Weeks 4, 12, and 24
Achievement of Success in Worst Itch Numeric Rating Scale (WI-NRS) Score Over Time
The percentage of participants achieving WI-NRS success is reported. WI-NRS "success" is defined as a ≥4 point improvement from a baseline score of ≥4. The WI-NRS is a simple, single item scale to assess the participant-reported severity of this symptom, on a scale ranging from 0 ("no itch") to 10 ("worst imaginable itch") the participant experienced in the past 24 hours. Higher scores indicate greater symptom severity.
Time frame: Weeks 4, 12, and 24
| Milestone | Cohort 1 Group 1: Prior Roflumilast Cream 0.3% | Cohort 1 Group 2: Prior Roflumilast Cream 0.3% | Cohort 2: No Prior Roflumilast Cream |
|---|---|---|---|
| Started | 264 | 9 | 60 |
| Completed | 232 | 6 | 56 |
| Not completed | 32 | 3 | 4 |
| Withdrew: Lost to follow-up | 15 | 1 | 1 |
| Withdrew: Withdrawal by subject | 12 | 1 | 3 |
| Withdrew: Miscellaneous | 2 | 1 | 0 |
| Withdrew: Noncompliance | 2 | 0 | 0 |
| Withdrew: Adverse event | 1 | 0 | 0 |
The percentage of participants with ≥TEAE is reported.
| percentage of participants | Cohort 1 Group 1: Prior Roflumilast Cream 0.3% | Cohort 1 Group 2: Prior Roflumilast Cream 0.3% | Cohort 2: No Prior Roflumilast Cream |
|---|---|---|---|
| Percentage of Participants With ≥1 Treatment-Emergent Adverse Events (TEAEs) | 26.1 | 33.3 | 56.7 |
The percentage of participants with ≥1 SAE is reported.
| percentage of participants | Cohort 1 Group 1: Prior Roflumilast Cream 0.3% | Cohort 1 Group 2: Prior Roflumilast Cream 0.3% | Cohort 2: No Prior Roflumilast Cream |
|---|---|---|---|
| Percentage of Participants With ≥1 Serious Adverse Events (SAEs) | 1.1 | 0 | 1.7 |
The percentage of participants achieving an IGA score of 0 or 1 is reported. The IGA is a 5-point scale assessing the severity of skin issues, with scores ranging from 0 ('clear') to 4 ('severe'), and higher scores indicate greater symptom severity.
| percentage of participants | Cohort 1 Group 1: Prior Roflumilast Cream 0.3% | Cohort 1 Group 2: Prior Roflumilast Cream 0.3% | Cohort 2: No Prior Roflumilast Cream |
|---|---|---|---|
| Week 4 | 41.2 | 33.3 | 26.7 |
| Week 12 | 58.1 | 83.3 | 56.1 |
| Week 24 | 49.1 | 83.3 | 73.2 |
The Kaplan-Meier (KM) median DOR (days) of IGA score of clear or almost clear is reported. The IGA is a 5-point scale assessing the severity of skin issues, with scores ranging from 0 ('clear') to 4 ('severe'), and higher scores indicate greater symptom severity. The duration of response starts with the first assessment of clear or almost clear, which could be as early as the Week 2 assessment in the feeder study, and continues until the participant's disease worsens or completes their involvement in the study. Therefore, the time variable could be as long as 30 weeks, 6 weeks in the feeder study plus 24 weeks in the ARQ-151-306 study.
| days | Cohort 1 Group 1: Prior Roflumilast Cream 0.3% | Cohort 1 Group 2: Prior Roflumilast Cream 0.3% | Cohort 2: No Prior Roflumilast Cream |
|---|---|---|---|
| Duration of Response (DOR) for Participants Achieving an IGA Score of 'Clear' or 'Almost Clear' | 189 (1 to 222) | NA (1 to 190) | NA (1 to 147) |
The percentage of participants worsening to IGA Score of ≥2 after achieving an IGA score of clear or almost clear is reported. The IGA is a 5-point scale assessing the severity of skin issues, with scores ranging from 0 ('clear') to 4 ('severe'), and higher scores indicate greater symptom severity.
| percentage of participants | Cohort 1 Group 1: Prior Roflumilast Cream 0.3% | Cohort 1 Group 2: Prior Roflumilast Cream 0.3% | Cohort 2: No Prior Roflumilast Cream |
|---|---|---|---|
| Return to IGA Score of ≥2 After Achieving an IGA Score of 'Clear' or 'Almost Clear' | 25.8 | 11.1 | 5.0 |
The percentage of participants achieving PASI-50 is reported. The PASI is widely used for the measurement of severity of psoriasis. PASI combines the assessment of the severity of lesions and the area affected into a single score in the range from 0 (no disease) to 72 (maximal disease), with higher scores indicating greater symptom severity.
| percentage of participants | Cohort 1 Group 1: Prior Roflumilast Cream 0.3% | Cohort 1 Group 2: Prior Roflumilast Cream 0.3% | Cohort 2: No Prior Roflumilast Cream |
|---|---|---|---|
| Week 4 | 65.6 | 55.6 | 63.3 |
| Week 12 | 75.2 | 100.0 | 84.2 |
| Week 24 | 68.8 | 83.3 | 85.7 |
The percentage of participants achieving PASI-75 is reported. The PASI is widely used for the measurement of severity of psoriasis. PASI combines the assessment of the severity of lesions and the area affected into a single score in the range from 0 (no disease) to 72 (maximal disease), with higher scores indicating greater symptom severity.
| percentage of participants | Cohort 1 Group 1: Prior Roflumilast Cream 0.3% | Cohort 1 Group 2: Prior Roflumilast Cream 0.3% | Cohort 2: No Prior Roflumilast Cream |
|---|---|---|---|
| Week 4 | 32.0 | 33.3 | 23.3 |
| Week 12 | 49.2 | 50.0 | 63.2 |
| Week 24 | 42.7 | 50.0 | 69.6 |
The percentage of participants achieving PASI-90 is reported. The PASI is widely used for the measurement of severity of psoriasis. PASI combines the assessment of the severity of lesions and the area affected into a single score in the range from 0 (no disease) to 72 (maximal disease), with higher scores indicating greater symptom severity.
| percentage of participants | Cohort 1 Group 1: Prior Roflumilast Cream 0.3% | Cohort 1 Group 2: Prior Roflumilast Cream 0.3% | Cohort 2: No Prior Roflumilast Cream |
|---|---|---|---|
| Week 4 | 12.0 | 11.1 | 6.7 |
| Week 12 | 26.4 | 50.0 | 33.3 |
| Week 24 | 23.9 | 50.0 | 51.8 |
The percentage of participants achieving PASI-100 is reported. The PASI is widely used for the measurement of severity of psoriasis. PASI combines the assessment of the severity of lesions and the area affected into a single score in the range from 0 (no disease) to 72 (maximal disease), with higher scores indicating greater symptom severity.
| percentage of participants | Cohort 1 Group 1: Prior Roflumilast Cream 0.3% | Cohort 1 Group 2: Prior Roflumilast Cream 0.3% | Cohort 2: No Prior Roflumilast Cream |
|---|---|---|---|
| Week 4 | 7.2 | 11.1 | 3.3 |
| Week 12 | 15.4 | 33.3 | 21.1 |
| Week 24 | 15.4 | 33.3 | 35.7 |
The percentage of participants achieving WI-NRS success is reported. WI-NRS "success" is defined as a ≥4 point improvement from a baseline score of ≥4. The WI-NRS is a simple, single item scale to assess the participant-reported severity of this symptom, on a scale ranging from 0 ("no itch") to 10 ("worst imaginable itch") the participant experienced in the past 24 hours. Higher scores indicate greater symptom severity.
| percentage of participants | Cohort 1 Group 1: Prior Roflumilast Cream 0.3% | Cohort 1 Group 2: Prior Roflumilast Cream 0.3% | Cohort 2: No Prior Roflumilast Cream |
|---|---|---|---|
| Week 4 | 56.7 | 25.0 | 53.8 |
| Week 12 | 67.1 | 50.0 | 70.3 |
| Week 24 | 60.2 | 50.0 | 72.2 |
Collected over Up to ~24 weeks. Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Cohort 1 Group 1: Prior Roflumilast Cream 0.3% | 0/264 (0%) | 3/264 (1.1%) | 10/264 (3.8%) |
| Cohort 1 Group 2: Prior Roflumilast Cream 0.3% | 0/9 (0%) | 0/9 (0%) | 3/9 (33.3%) |
| Cohort 2: No Prior Roflumilast Cream | 0/60 (0%) | 1/60 (1.7%) | 26/60 (43.3%) |
| Event | Cohort 1 Group 1: Prior Roflumilast Cream 0.3% | Cohort 1 Group 2: Prior Roflumilast Cream 0.3% | Cohort 2: No Prior Roflumilast Cream |
|---|---|---|---|
| AppendicitisInfections and infestations | 0/264 | 0/9 | 1/60 |
| PalpitationsCardiac disorders | 1/264 | 0/9 | 0/60 |
| COVID-19 pneumoniaInfections and infestations | 1/264 | 0/9 | 0/60 |
| DehydrationMetabolism and nutrition disorders | 1/264 | 0/9 | 0/60 |
| Polycythaemia veraNeoplasms benign, malignant and unspecified (incl cysts and polyps) | 1/264 | 0/9 | 0/60 |
| SyncopeNervous system disorders | 1/264 | 0/9 | 0/60 |
| Event | Cohort 1 Group 1: Prior Roflumilast Cream 0.3% | Cohort 1 Group 2: Prior Roflumilast Cream 0.3% | Cohort 2: No Prior Roflumilast Cream |
|---|---|---|---|
| NasopharyngitisInfections and infestations | 4/264 | 0/9 | 16/60 |
| HeadacheNervous system disorders | 8/264 | 0/9 | 12/60 |
| InfluenzaInfections and infestations | 4/264 | 0/9 | 7/60 |
| Abdominal pain upperGastrointestinal disorders | 1/264 | 1/9 | 1/60 |
| Application site painGeneral disorders | 1/264 | 1/9 | 0/60 |
| Skin bacterial infectionInfections and infestations | 0/264 | 1/9 | 0/60 |
| Decreased appetiteMetabolism and nutrition disorders | 3/264 | 1/9 | 0/60 |
| PyrexiaGeneral disorders | 0/264 | 0/9 | 4/60 |
| Age, Continuous(years) | Cohort 1 Group 1: Prior Roflumilast Cream 0.3% | Cohort 1 Group 2: Prior Roflumilast Cream 0.3% | Cohort 2: No Prior Roflumilast Cream | Total |
|---|---|---|---|---|
| Mean | 47.9 ± 15.79 | 9.8 ± 3.80 | 7.5 ± 3.52 | 39.6 ± 21.57 |
| Sex: Female, Male(Participants) | Cohort 1 Group 1: Prior Roflumilast Cream 0.3% | Cohort 1 Group 2: Prior Roflumilast Cream 0.3% | Cohort 2: No Prior Roflumilast Cream | Total |
|---|---|---|---|---|
| Female | 108 | 4 | 23 | 135 |
| Male | 156 | 5 | 37 | 198 |
| Ethnicity (NIH/OMB)(Participants) | Cohort 1 Group 1: Prior Roflumilast Cream 0.3% | Cohort 1 Group 2: Prior Roflumilast Cream 0.3% | Cohort 2: No Prior Roflumilast Cream | Total |
|---|---|---|---|---|
| Hispanic or Latino | 60 | 4 | 40 | 104 |
| Not Hispanic or Latino | 204 | 5 | 20 | 229 |
| Unknown or Not Reported | 0 | 0 | 0 | 0 |
| Race/Ethnicity, Customized(Participants) | Cohort 1 Group 1: Prior Roflumilast Cream 0.3% | Cohort 1 Group 2: Prior Roflumilast Cream 0.3% | Cohort 2: No Prior Roflumilast Cream | Total |
|---|---|---|---|---|
| American-Indian or Alaska Native | 1 | 0 | 1 | 2 |
| Asian | 13 | 0 | 4 | 17 |
| Black or African-American | 15 | 0 | 39 | 54 |
| Native Hawaiian or Other Pacific Islander | 2 | 0 | 0 | 2 |
| White | 222 | 9 | 15 | 246 |
| Not reported | 0 | 0 | 0 | 0 |
| Other | 11 | 0 | 0 | 11 |
| Multiple | 0 | 0 | 1 | 1 |
PDFs hosted by the registry, ClinicalTrials.gov.
Ran from Feb 2020 to primary completion in Jan 2024, 47 months.
Results were first posted in Sep 2026, 2 years 7 months after primary completion. A results delay was requested in Jan 2025.
Of 217 industry-sponsored phase 3 interventional studies under Psoriasis, half reached primary completion within 15 months of starting (the median), counting those still running; a quarter within 10 and three quarters within 26. This study's 47 months is above that.
Counting every sponsor, half of 227 studies reached it within 15 months; a quarter within 10 and three quarters within 26.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Jul 2026. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Roflumilast
Arcutis Biotherapeutics, Inc. →